Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 16.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 12.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 11.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | “us” refer to AgeX Therapeutics, Inc. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; A |
| 01.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of certain secured loans and related fees. Item 5.02 - Departure of Directors or Certain Officers; Election of Directo |
Stammdaten
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Unternehmen & Branche
| Name | Serina Therapeutics, Inc. |
|---|---|
| Ticker | SER |
| CIK | 0001708599 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 18,3 Mio. USD |
| Beta | 0,10 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 130,000 | -19,182,000 | -1.91 | 6,951,000 | -37,000 |
| 2025-09-30 | 10-Q | 0 | -4,585,000 | -0.45 | 12,413,000 | 1,760,000 |
| 2025-06-30 | 10-Q | 130,000 | -6,448,000 | -0.66 | 8,941,000 | 1,802,000 |
| 2025-03-31 | 10-Q | 0 | -4,813,000 | -0.49 | 6,731,000 | 1,701,000 |
| 2024-12-31 | 10-K | 56,000 | -11,141,000 | -1.51 | 6,724,000 | 641,000 |
| 2024-09-30 | 10-Q | 14,000 | 1,410,000 | 0.13 | 7,435,000 | -13,774,000 |
| 2024-06-30 | 10-Q | 51,000 | 5,204,000 | 0.51 | 10,708,000 | -16,363,000 |
| 2024-03-31 | 10-Q | 5,000 | -15,015,000 | -5.38 | 10,856,000 | -4,309,000 |
| 2023-12-31 | 10-K | 3,153,000 | 5,269,000 | 0.73 | 8,968,000 | -32,294,000 |
| 2023-09-30 | 10-Q | 29,000 | 1,752,000 | 0.23 | 12,210,000 | -27,536,000 |
| 2023-06-30 | 10-Q | 7,000 | 808,000 | 0.11 | 12,277,000 | -22,175,000 |
| 2023-03-31 | 10-Q | 30,000 | 1,658,000 | 0.20 | 12,531,000 | -36,118,000 |
| 2022-12-31 | 10-K | 34,000 | -10,462,000 | -9.70 | 3,241,000 | -17,212,000 |
| 2022-09-30 | 10-Q | 9,000 | -2,435,000 | -0.06 | 2,008,000 | -15,104,000 |
| 2022-06-30 | 10-Q | 12,000 | -2,618,000 | -0.07 | 2,579,000 | -13,218,000 |
| 2022-03-31 | 10-Q | 5,000 | -2,706,000 | 2,716,000 | -11,547,000 | |
| 2021-12-31 | 10-K | 144,000 | -8,675,000 | 3,154,000 | -11,832,000 | |
| 2021-09-30 | 10-Q | 24,000 | -1,955,000 | 2,427,000 | -9,936,000 | |
| 2021-06-30 | 10-Q | 37,000 | -2,474,000 | 2,541,000 | -8,252,000 | |
| 2021-03-31 | 10-Q | 56,000 | -2,088,000 | 3,160,000 | -6,062,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-19 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -39,000 | 2.50 | -97,500.00 | -354,2% | |
| 2026-02-02 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -6,500 | 3.03 | -19,680.05 | -71,5% | |
| 2026-01-28 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -6,500 | 3.57 | -23,185.50 | -84,2% | |
| 2026-01-22 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -2,500 | 2.95 | -7,375.00 | -26,8% | |
| 2026-01-21 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -2,000 | 3.00 | -6,000.00 | -21,8% | |
| 2026-01-20 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -2,000 | 3.07 | -6,140.00 | -22,3% | |
| 2026-01-14 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -1,084 | 2.50 | -2,713.36 | -9,9% | |
| 2026-01-13 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -5,416 | 2.50 | -13,540.00 | -49,2% | |
| 2026-01-08 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -13,000 | 2.69 | -34,953.10 | -127,0% | |
| 2025-12-23 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -4,100 | 2.60 | -10,660.00 | -38,7% | |
| 2025-12-22 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -5,673 | 2.67 | -15,167.90 | -55,1% | |
| 2025-12-16 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -3,227 | 2.96 | -9,561.92 | -34,7% | |
| 2025-12-12 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -1,700 | 3.26 | -5,541.49 | -20,1% | |
| 2025-12-11 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -3,555 | 3.24 | -11,519.62 | -41,8% | |
| 2025-12-10 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -645 | 3.35 | -2,160.75 | -7,8% | |
| 2025-12-09 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -600 | 3.31 | -1,987.98 | -7,2% | |
| 2025-12-03 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -5,000 | 3.52 | -17,623.00 | -64,0% | |
| 2025-12-02 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -1,500 | 3.91 | -5,857.80 | -21,3% | |
| 2025-11-25 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -5,965 | 3.90 | -23,264.10 | -84,5% | |
| 2025-11-24 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -535 | 3.94 | -2,105.23 | -7,6% | |
| 2025-11-18 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -6,500 | 3.75 | -24,401.65 | -88,6% | |
| 2025-11-10 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -6,500 | 4.10 | -26,650.00 | -96,8% | |
| 2025-11-05 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -3,398 | 4.24 | -14,407.52 | -52,3% | |
| 2025-11-04 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -3,102 | 4.40 | -13,634.22 | -49,5% | |
| 2025-10-28 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -5,551 | 4.96 | -27,541.29 | -100,0% | |
| 2025-10-27 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -949 | 5.19 | -4,921.23 | -17,9% | |
| 2025-10-20 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -6,500 | 4.97 | -32,286.80 | -117,3% | |
| 2025-10-13 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -4,326 | 5.20 | -22,495.20 | -81,7% | |
| 2025-08-26 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -45,632 | 7.01 | -319,880.32 | -1162,0% | |
| 2025-08-25 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -2,042 | 5.65 | -11,537.30 | -41,9% | |
| 2025-08-20 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -2,077 | 5.10 | -10,592.70 | -38,5% | |
| 2025-08-18 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -2,227 | 5.25 | -11,691.75 | -42,5% | |
| 2025-08-12 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -5,500 | 5.25 | -28,875.00 | -104,9% | |
| 2025-08-04 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -5,500 | 5.17 | -28,435.00 | -103,3% | |
| 2025-07-29 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -4,196 | 6.50 | -27,274.00 | -99,1% | |
| 2025-07-28 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -6,500 | 5.89 | -38,285.00 | -139,1% | |
| 2025-07-21 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -6,500 | 5.34 | -34,710.00 | -126,1% | |
| 2025-07-14 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -6,500 | 5.01 | -32,565.00 | -118,3% | |
| 2025-07-07 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -6,500 | 5.67 | -36,855.00 | -133,9% | |
| 2025-06-30 | Moreadith Randall | Officer, Chief Scientific Officer | Open Market Sale | -6,500 | 5.78 | -37,570.00 | -136,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.